Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will present a corporate overview at the Jefferies 2020 Virtual Healthcare Conference, being held June 2-4, 2020
| NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present a corporate overview at the Jefferies 2020 Virtual Healthcare Conference, being held June 2-4, 2020.
Presentation Details:
About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada’s lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. Investor Contact: Tim McCarthy For Media Inquiries:
SOURCE Relmada Therapeutics, Inc. | ||||||||
Company Codes: NASDAQ-NMS:RLMD |
View original content to download multimedia:
